La cadena de opciones muestra datos clave de las opciones de acciones de Jin Medical International a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Jin Medical International..

Jin Medical International (NASDAQ:ZJYL) Bolsa, Cadena de Opciones

Jin Medical International

Jin Medical International Ltd offers rehabilitation equipment. It is primarily engaged in the design, development, manufacturing, and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's products are sold to distributors in both China and in overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, nursing products, and conlo products.

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International Ltd

Earnings

News

Solidion Technology Q3 EPS $(0.07), Including Non-Cash Loss On Issuance Of PIPE Common Stock And Warrants

President-elect Donald Trump announced former Congressman Sean Duffy to oversee the Department of Transportation (DOT) on Monday. 
Here's a look at how the latest Trump selection could affect companies in <a href="https://www.benzinga.com/news/24/11/42053292/trump-picks-sean-duffy-as-next-transportation-secretary-says-he-will-usher-in-the-golden-age-of-travel">the transportation sector. </a>
The Details: Duffy, who served in the U.S. House of Representatives from 2011 to 2019, most recently worked as Fox News Media host. He left the position on Monday, according <a href="https://www.nytimes.com/2024/11/18/us/politics/sean-duffy-trump-transportation-dot.html">to</a> the New York Times.
Duffy is the second Fox News employee to be nominated by Trump for a cabinet position. Last week, Trump picked Fox News host Pete Hegseth as Defense Secretary despite <a href="https://www.benzinga.com/news/24/11/41952962/trumps-surprise-defense-secretary-pick-pete-hegseth-jolts-wall-street">lack of government experience</a>.
In 1997, he was a cast member on MTV's "The Real World: Boston.&#8221;
As Transportation Secretary, Duffy would be in charge of major federal agencies, including the Federal Aviation Administration (FAA) and the National Highway Traffic Safety Administration (NHTSA). 
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
"He will prioritize Excellence, Competence, Competitiveness and Beauty when rebuilding America's highways, tunnels, bridges and airports. He will ensure our ports and dams serve our Economy without compromising our National Security, and he will make our skies safe again by eliminating DEI for pilots and air traffic controllers," Trump said in his announcement.&nbsp;&nbsp;
<h3 class="wp-block-heading">Air Travel</h3>
If approved by the Senate, Duffy can be expected to address ongoing aviation <a href="https://www.benzinga.com/general/travel/24/11/42014904/boeing-begins-layoffs-is-the-737-max-recovery-enough-to-lift-ba-stock">safety issues</a>. This could include matters relating to Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and air traffic control challenges. As part of Trump's focus on efficiency, Duffy could potentially work to enhance safety measures while streamlining regulations. 
Major airline companies like Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) may be affected by potential policy and regulatory changes, as well. 
<h3 class="wp-block-heading">&#8216;Overall Negative For EV Industry&#8217;</h3>
The DOT also oversees the National Highway Traffic Safety Administration (NHTSA) which is expected to focus on regulatory frameworks for electric vehicles and autonomous driving technologies in the near term.  The NHTSA is likely to establish guidelines for emerging technologies like Tesla, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) autonomous driving software. 
Recent reports suggest Trump has plans to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42046316/trump-set-to-hand-musk-golden-path-for-tesla-after-reversing-course-on-autonomous-vehicle-ban">ease restrictions</a> on self-driving vehicles, which could help companies like Tesla expand FSD and bring robotaxis to the market.
Tesla CEO Elon Musk campaigned heavily for Trump and provided millions to his campaign coffers ahead of Election Day.
At the same time, it seems likely that the incoming Trump administration <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">will eliminate </a>or reduce many of the EV purchase incentives included in the Biden administration&#8217;s Inflation Reduction Act (IRA). 
Wedbush analysts said that Tesla&#8217;s rivals, U.S.-based EV startups like Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), could face a major set-back if Trump rolls back current EV tax incentives and rebates, as reports suggest. 
"We believe a Trump presidency would be an overall negative for the EV industry as likely the EV rebates/tax incentives get pulled," Wedbush analysts wrote.&nbsp;
<h3 class="wp-block-heading">Railroads</h3>
If Duffy is confirmed, he will also oversee the Federal Railroad Administration (FRA), which is responsible for safety measures across the rail network. He may address safety concerns following incidents like the East Palestine <a href="https://www.benzinga.com/news/24/04/38240139/norfolk-southern-to-pay-600m-in-ohio-train-derailment-lawsuit">derailment in 2023</a>.
Duffy will also manage billions in federal grants aimed at improving rail infrastructure and upgrading aging rail systems to enhance efficiency and safety. Railroad companies including CSX Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), Norfolk Southern Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) and Union Pacific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) may benefit from such improvement projects. 
Investors can also monitor the broader transportation sector through ETFs which track its performance including the iShares Trust iShares U.S. Transportation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYT#BATS">IYT</a>) and the First Trust Nasdaq Transportation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXR#NASDAQ">FTXR</a>). 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock&nbsp;

Politics

Travel

Movers

General

FTXR

iShares Dow Jones Transportation Average Index Fund

LCID

RIVN

TSLA

What Trump's DOT Pick Could Mean For EVs, Airlines, Railroad Stocks

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Markets

$BTC

$ETH

GOOG

MSFT

NVDA

Real Vision's Raoul Pal Says AI Open-Source Models Are So Big And Important That They Could Use Blockchain To Secure Their Code From Government Interference, Other AI

It is payable January 13, 2025 to shareholders of record December 30, 2024.

Dividends

McCormick Increases Quarterly Dividend From $0.42 To $0.45 Per Share On Its Common Stock

Real Vision's Raoul Pal Says Tesla's Robotaxis Could Likely Use Blockchain, Crypto Payments

Guidance

QFIN

Qifu Technology Expects Q4 Net Income Of RMB1.75B - RMB1.85B, Adj Net Income Of RMB1.80B -RMB1.90B, Representing 57% - 65% Year-on-year Growth

Real Vision's Raoul Pal Says The 'AI Layer' Of The Internet Is Coming; We Already Have Blockchain; Says This Is The 'Security Truth Layer,' Says We'll Need To Figure Out What Is Real Or Not For Everything

Qifu Technology Expects To See Relatively Stable Overall Risk Performance In The Coming Quarters As It Remains Vigilant In Risk Management Under Current Macro Environment

Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.83) by 18.07 percent. The company reported quarterly sales of $2.51 million which missed the analyst consensus estimate of $3.42 million by 26.71 percent. This is a 17.17 percent decrease over sales of $3.03 million the same period last year.

Earnings Misses

WKHS

Workhorse Gr Q3 2024 GAAP EPS $(0.98) Misses $(0.83) Estimate, Sales $2.51M Miss $3.42M Estimate

Real Vision's Raoul Pal Says Countries Will Use Crypto To Solve Interest Payments For National Debt

<ul>
<li>10-year PPA to deliver power from Argo and Brookfield's Smoky Mountain Hydro Facilities located in east Tennessee and western North Carolina</li>
<li>The hydro facilities will provide 377 MW of reliable, clean energy to meet demand growth in TVA's service territory</li>
<li>The PPA will support TVA's energy transition goal to achieve net-zero by 2050</li>
</ul>
Tennessee Valley Authority ("TVA") together with Argo Infrastructure Partners, LP ("Argo") and Brookfield Asset Management ("Brookfield") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/BAM#TSX">BAM</a>), with its listed affiliate Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>, BEPC, TSX:<a class="ticker" href="https://www.benzinga.com/stock/BEP#TSX">BEP</a>, BEPC))) today announced the signing of a landmark 10-year power purchase agreement ("PPA") with power to be delivered by the Cheoah, Calderwood, Chilhowee and Santeetlah dams, together known as the Smoky Mountain Hydroelectric facilities ("Smoky"), which is jointly owned by Argo and Brookfield.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20241119725256/en/">https://www.businesswire.com/news/home/20241119725256/en/</a>
Smoky will begin delivering power through the PPA starting in 2025 and over the next decade, will supply more than 14 gigawatt hours of carbon-free energy to TVA customers, advancing TVA's transition towards its 2050 net-zero goal.
Smoky currently owns and operates a 377-megawatt portfolio of four hydroelectric power facilities across east Tennessee and western North Carolina. This portfolio generates an annual average of 1.4 million megawatt-hours of carbon-free energy—equivalent to approximately 1.1 million tons of CO2 emissions avoided each year.

Contracts

TSX:BAM

TSX:BEP

Tennessee Valley Authority Together With Argo Infrastructure Partners And Brookfield Asset Management, With Its Listed Affiliate Brookfield Renewable Announces The Signing Of A Landmark 10-Year PPA With Power To Be Delivered By The Smoky Mountain Hydroelectric Facilities, Which Is Jointly Owned By Argo And Brookfield

Pantera Capital's Dan Morehead Says Yield-Bearing Stablecoins Are Going To Be Big

Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) reported financial results for the fourth quarter of fiscal 2024 after the bell on Tuesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/24/11/n42074717/dolby-laboratories-reports-fourth-quarter-and-fiscal-year-2024-financial-results">from the quarter</a>.
<ul>
<li>Q4 Revenue: $304.81 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $307.94 million</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: 81 cents, versus estimates of 70 cents</li>
</ul>
Dolby said it repurchased approximately 251,000 shares during the quarter. The company had approximately $402 million remaining under its stock repurchase authorization at the quarter&#8217;s end. The company also declared a cash dividend of 33 cents per share payable on Dec. 10 to shareholders of record as of Dec. 3.
&#8220;As we enter fiscal 2025, we have strong momentum with Dolby Atmos and Dolby Vision, our imaging patent portfolio has gotten stronger with the GE Licensing acquisition, and we are excited about our opportunity with Dolby.io, which is well positioned to provide real-time interactive experiences for sports and entertainment,&#8221; said Kevin Yeaman, president and CEO of Dolby.
Don&#8217;t Miss: <a href="https://www.benzinga.com/24/11/42073589/target-q3-earnings-preview-analysts-expect-revenue-eps-growth-attention-may-quickly-turn-to-holiday-quarter">Target Q3 Earnings Preview: Analysts Expect Revenue, EPS Growth As Attention Turns To Holiday Quarter</a>
Outlook: Dolby expects first-quarter revenue to be in the range of $330 million to $360 million versus estimates of $307.94 million. The company anticipates first-quarter earnings of 96 cents to $1.11 per share versus estimates of 70 cents per share.
Dolby sees full-year 2025 revenue in the range of $1.33 billion to $1.39 billion versus estimates of $1.28 billion. The company expects full-year earnings to be between $3.99 and $4.14 per share versus estimates of $3.70 per share. 
Dolby&#8217;s strong forecast appears to be helping push shares higher after hours. The company&#8217;s management team will further discuss the quarter on a call with analysts and investors at 5 p.m. ET.
DLB Price Action: Dolby shares were up 11.06% in after hours, trading at $78.75 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Pixabay.

Dolby Laboratories Reports Q4 Earnings, Provides Strong Forecast For 2025, Shares Surge

Digital Chamber Founder, CEO Perianne Boring Says Stablecoins Are A Way To Extend Dollar Dominance

Update on Share Repurchase Plan of 2024
On March 12, 2024, the Company's board of directors approved a share repurchase plan whereby the Company is authorized to repurchase its ADSs or Class A ordinary shares with an aggregate value of up to US$350 million during the 12-month period from April 1, 2024.
As of November 19, 2024, the Company had in aggregate purchased approximately 13.7 million ADSs in the open market for a total amount of approximately US$298 million (inclusive of commissions) at an average price of US$21.7 per ADS pursuant to the share repurchase plan.
New US$450 Million Share Repurchase Plan of 2025
On November 19, 2024, the Company's board of directors approved a new share repurchase plan whereby the Company is authorized to repurchase up to US$450 million worth of its ADSs or Class A ordinary shares over the next 12 months starting from January 1, 2025. The share repurchases may be effected from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and will be implemented in accordance with applicable rules and regulations.

Buybacks

Qifu Technology Approves A New Share Repurchase Plan Whereby The Company Is Authorized To Repurchase Up To $450M Worth Of Its ADS Or Class A Ordinary Shares Over The Next 12 Months Starting From January 1, 2025

ZTO Express (Cayman) Q3 2024 Adj EPADS $0.41 Inline With Estimate, Sales $1.52B Beat $1.48B Estimate

– Unique Position at the Edge Drives an Expanded TAM of ~$900 billion by 2030 –
– Transformation Redefines Qualcomm, Diversifies Customer Base and Accelerates Growth –
Qualcomm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), a connected computing leader, today outlined its significant opportunities for growth and diversification at its 2024 Investor Day. The company's unique position at the edge is driving access to an expanded TAM of approximately $900 billion by 2030, with more than 50 billion cumulative connected edge device shipments expected from 2024 through 2030.
"Qualcomm's focus on diversification and industry-leading technology roadmap has significantly strengthened the Company's growth profile," said Cristiano Amon, President &amp; CEO, Qualcomm Incorporated. "As generative AI accelerates demand for our technology and we become increasingly relevant across multiple industries, Qualcomm is well positioned to address a $900 billion opportunity by 2030 across an expanding ecosystem of new customers and partners."
Qualcomm provided new five-year financial targets for its QCT business, including:
<ul>
<li>Automotive and IoT to drive combined revenues of $22 billion by FY29
<ul>
<li>Automotive revenues to grow to $8 billion by FY29</li>
<li>IoT to grow to $14 billion in revenues by FY29
<ul>
<li>PC to grow to $4 billion in revenues by FY29</li>
<li>Industrial to grow to $4 billion in revenues by FY29</li>
<li>XR to grow to more than $2 billion in revenues by FY29</li>
<li>Rest of IoT to grow to $4 billion in revenues by FY29</li>
</ul>
</li>
</ul>
</li>
</ul>
At its Investor Day, Cristiano Amon, along with Akash Palkhiwala, Chief Financial Officer and Chief Operating Officer, Qualcomm Incorporated; Nakul Duggal, Group General Manager of Automotive, Industrial and Cloud, Qualcomm Technologies, Inc.; Alex Katouzian, Group General Manager of Mobile, Compute and XR, Qualcomm Technologies, Inc.; and Durga Malladi, Senior Vice President and General Manager of Technology Planning &amp; Edge Solutions, Qualcomm Technologies, Inc., outlined the company's traction and expanded opportunities for diversification. Their full presentations and a replay of the event are available <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.qualcomm.com%2Fcompany%2Fevents%2Finvestor-day&amp;esheet=54155505&amp;newsitemid=20241119340813&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=e12dd2c60637f69d6a4a0ff89c1b9e8c">here</a>.

QCOM

Qualcomm Provides New 5-Year Financial Targets For Its QCT Business, All By FY29 Include: Automotive And IOT To Drive Combined Revenues Of $22B; Automotive Revenues To Grow To $8B; IOT To Grow To $14B In Revenues; PC To Grow To $4B In Revenues; Industrial To Grow To $4B In Revenues; XR To Grow To More Than $2B In Revenues; Rest Of IOT To Grow To $4B In Revenues

OGroups Maja Vujinovic Says Stablecoins Are A Political Issue, A Security Issue

Qifu Technology Q3 2024 Adj EPADS $1.76 Beats $1.40 Estimate, Sales $622.70M Beat $577.71M Estimate

Glauber Contessoto, also known as "<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40876130/dogecoin-millionaire-highlights-pepe-and-dogecoin-as-two-biggest-meme-narratives-for-2025-">Dogecoin millionaire</a>," expressed bullish sentiments on Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), predicting a parabolic rise for the second-largest cryptocurrency.
What Happened: While acknowledging current market frustration over ETH&#8217;s underperformance, he believes Ethereum is well-positioned for future growth.
He highlighted Ethereum&#8217;s appeal to institutional investors, describing it as a trusted blockchain for building applications, unlike Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), which he labeled a &#8220;meme coin blockchain&#8221; attracting high-liquidity traders. 
Contessoto asserts that institutional investment in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) will eventually shift to Ethereum for development purposes.
His <a href="https://x.com/ProTheDoge/status/1858827991846908327">prediction</a> sees Ethereum potentially hitting $15,000 this cycle if Bitcoin climbs to $200,000, emphasizing its role as the next step for institutional players
Trader CrediBULL Crypto <a href="https://x.com/CredibleCrypto/status/1858945075599872047">warned</a> that while Bitcoin is testing its range highs, Ethereum remains stagnant. 
If Bitcoin faces a rejection at these levels, Ethereum could follow suit. 
The trader hopes for either an Ethereum rally to match Bitcoin&#8217;s gains or a price dip below $2,800, presenting a buying opportunity.
Also Read: <a href="https://www.benzinga.com/news/events/24/11/42068771/bitcoin-ethereum-etfs-and-tokenized-assets-broaden-investor-access">Bitcoin, Ethereum ETFs And Tokenized Assets &#8216;Broaden&#8217; Investor Access</a>
Why It Matters: Despite concerns over Ethereum&#8217;s sluggish performance, Contessoto and others highlight its strong potential for long-term growth, driven by institutional adoption and its robust blockchain ecosystem.
IntoTheBlock data shows large transaction volume increasing by 79.9% and daily active addresses falling by 6.7%. Transactions greater than $100,000 are up from 5,187 to 8,210 in a single day. Exchanges netflows are up by 527%.
Coinglass data reports Ethereum open interest spiked to $18 billion.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41927598/raoul-pal-predicted-bitcoin-to-hit-250-000-but-he-thinks-ethereum-could-outperform-under-d">Raoul Pal Predicted Bitcoin To Hit $250,000—But He Thinks Ethereum Could Outperform Under Donald Trump&#8217;s Administration</a></li>
</ul>

$SOL

'Dogecoin Millionaire' Predicts Ethereum To Hit $15,000 If Bitcoin Cracks $200,000

PHIO and MGRM among healthcare movers

VERI, CHEK and MESO are among pre market gainers

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has regained compliance with Nasdaq's public holders r...

Jin Medical Regains Nasdaq Compliance, Aims for Timely Filing

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical Technologies Ltd. faces scrutiny as its former auditor, DNTW Toronto LLP,...

Jin Medical Auditor Resigns Amid Dispute

WIRE, CUTR and USEG are among premarket  gainers

Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has successfully regained compliance with Nasdaq's fil...

Jin Medical Regains Nasdaq Compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
June may not be the first month you consider when you plan to invest, but this isn&rsquo;t a month that should be overlooked. June is an ideal time to look for A-rated <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> to diversify your portfolio and lead to some potentially lucrative returns.



Penny stocks are shares of companies with stock valued under $5. It&rsquo;s appealing to investors since they can acquire a significant stake in a company with a small investment.



However, not all penny stocks are created equal, and the risks associated with them can be substantial. This is where A-rated penny stocks come into play.



A-rated penny stocks get their rankings from the Portfolio Grader, which assigns stocks a letter grade based on earnings performance, growth, analyst sentiment and buying momentum. By keeping your eye on A-rated penny stocks, you&rsquo;re assured of getting the best of these low-priced stocks and setting yourself up for a better overall return.



And with June being a popular month for companies to file earnings reports, investors are armed with new information about these companies&rsquo; performance and outlook.



There are seven A-rated penny stocks on today&rsquo;s list, and any of them would be a solid addition to a portfolio while mitigating the risks that are commonly associated with smaller companies.



<h2>Lexaria Bioscience (LEXX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>Biotech companies can be challenging investments. Bringing a drug to market is no small feat, as it requires millions of dollars in research and development and multiple successful clinical trials before you can even consider seeking regulatory approval and achieve commercialization.



But Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) is an exception to the rule. The company is the creator of DehydraTECH, which is a drug delivery technology that improves the way active drugs enter the bloodstream.



DehydraTECH increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled tablets, capsules and oral suspensions because it can mask the taste of medications.



Biotechs can incorporate the DehydraTECH platform into any of their oral medications to make them more effective and tolerable for patients.



Any drug delivery system that makes medications more effective and more tolerable to patients is going to be popular in the biotech field.



The DehydraTECH platform increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled products because it can mask the taste of medications.



At the end of the <a href="https://ir.lexariabioscience.com/financial-information/financial-results">second quarter</a>, Lexaria was in a strong cash position, with $4.7 million on hand. Revenue in the quarter was only $145,000, but that is better than the $20,000 the company received in the second fiscal quarter of 2023. The company reported a loss of $668,000, but its losses are significantly dropping as the company edges toward profitability.



LEXX stock is up 130% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>JanOne (JAN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div>JanOne (NASDAQ:<a href="https://investorplace.com/stock-quotes/jan-stock-quote/">JAN</a>) is yet another bioscience company. It is developing nonaddictive treatments for conditions that cause severe pain. Its work is dedicated to helping people manage their pain without getting hooked on a treatment and developing a dependency for a drug, such as opioids.



Its most promising drug in the pipeline is a treatment for peripheral artery disease. The drug candidate has successfully completed Phase 2A trials and is awaiting Phase 2B testing to treat the disease and the pain associated with peripheral artery disease.



In addition, JanOne has a wholly owned subsidiary called <a href="https://ir.janone.com/news-events/press-releases/detail/71/janones-subsidiary-alt5-reports-91-year-over-year">ALT5 Sigma</a>, which is a fintech company that provides next-generation blockchain powered technologies. The company processed $289 million in cryptocurrency transactions in April and May combined, which was a 91% increase from a year ago.



JanOne offers an interesting way to invest in biotech and also play the cryptocurrency space. The stock is up 333% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Ocugen (OCGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/ocgn1600-300x169.png" alt="Person holding smartphone with logo of US biopharmaceutical company Ocugen Inc. (OCGN) on screen in front of website. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>As a small biotech company headquartered in Pennsylvania, Ocugen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocgn-stock-quote/">OCGN</a>) is making its mark by developing and commercializing gene and cell therapies.



The company is also getting a nice boost on June 28 when it joins the Russell 3000 index, which measures the performance of the largest 3,000 U.S. companies. Its inclusion means that Ocugen stock will be included in exchange traded funds and products that track the Russell 3000.



Ocugen is working on a breakthrough modifier gene therapy product that might treat multiple retinal diseases with a single product. It also has several products in various phases of testing to treat eye diseases.



Ocugen showed $13.2 million in operating expenses for the first quarter and had $26.4 million of cash on hand. It posted a loss of 5 cents per share versus a loss of 8 cents per share a year ago.



Losses for small biotech companies are to be expected as it takes time and money to bring new therapies to market. But OCGN stock is one of the better penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> you can buy, as the stock is up 124% so far this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Kuke Music (KUKE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/music_1600-300x169.jpg" alt="A photo of someone writing out music on staff paper with guitars in the background."><div>Source: Kemedo/ShutterStock.com</div></div>Kuke Music (NYSE:<a href="https://investorplace.com/stock-quotes/kuke-stock-quote/">KUKE</a>) is a digital music company in China. The company is a leading provider of classical music licensing, subscriptions and smart education services in China.



The company leverages its diverse content offerings and experience in music education to provide smart music education products, including Kuke smart pianos and Kuke smart teaching systems.



The company is also the organizer of the Beijing Music Festival and is working to get into the AI music field through a <a href="https://finance.yahoo.com/news/kuke-jidou-join-forces-ai-122000084.html">partnership</a> with Shanghai Jidou Science and Technology, which will see Kuke lauch an AI music application through a digital automotive software platform that Jidou develops for more than a dozen automotive companies.



<a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318325464&amp;type=HTML&amp;cdn=2794ad5ad1fb979a4aae2110f8badbd2&amp;formType=20-F&amp;dateFiled=2024-05-15&amp;cik=0001809158&amp;symbol=0001809158&amp;companyName=">Kuke and its subsidiaries</a> reported revenue in 2023 of 106.9 million Chinese yuan ($14.7 million) and a loss of 65.8 million Chinese yuan. But the AI music partnership provides a path for Kuke to turn those losses into profits.



KUKE stock is up 101% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Jin Medical (ZJYL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-single-300x169.jpg" alt="A close up photo of a penny. Penny Stocks to Buy"><div>Source: Shutterstock</div></div>Jin Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/zjyl-stock-quote/">ZJYL</a>) is another Chinese penny stock. The company makes and sells wheelchairs and other products for the elderly and those with disabilities.



The company operates two manufacturing plants with approximately 228,257 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. And it has relationships with more than 40 distributors in China and distributors in 20 other regions.



The majority of the company&rsquo;s wheelchair products, which includes 30 models, are sold in China and Japan.



As a Chinese company, Jin doesn&rsquo;t report its financials as often as those based in the U.S. But its <a href="https://ir.zhjmedical.com/se%D1%81filings">most current financial report</a> for the 2023 fiscal year (ending Sept. 30, 2023), included revenue of $19.8 million, up 3% from a year ago. 



Profits of $6.7 million were up 9.5% from the 2022 fiscal year, and total net income of $2.87 million was a 6.3% improvement from the previous year.



ZJYL stock, which had its initial public offering only a year ago, is having a rough 2024. The company performed a <a href="https://investorplace.com/2024/02/why-is-jin-medical-international-zjyl-stock-moving-today/">20-for-1 stock split,</a> which brought the stock price down from $217 to roughly $13.50. However, the stock has been slipping ever since, and is down in penny stock territory.



However, I&rsquo;m expecting a rebound based on the company&rsquo;s financials, and the stock currently maintains its &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Caravelle International (CACO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/tech-stocks-1600-300x169.png" alt="A hexagonal grid with different tech-related icons; Tech stocks illustration. Best Tech stocks. tech stocks trading at bargain prices"><div>Source: whiteMocca / Shutterstock</div></div>Caravelle International (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/">CACO</a>) is a global ocean technology company with headquarters in Singapore. The company has routes to 50 companies and serves more than 100 ports.



Caravelle&rsquo;s innovation lies in its work with shipping and lumber industries. The company invented a patent pending process called CO-Tech, which uses the heat from its ships&rsquo; exhaust to dry wood during transportation.



Caravelle says the process is an improvement from the lumber industry&rsquo;s practice of building and maintaining wood drying facilities and the energy required to heat the wood in those facilities.



Contrast this to the traditional wood desiccation process where lumber companies must build and maintain expensive wood drying facilities, spend money on energy to heat the wood, and emit massive amounts CO2.



The company already has a <a href="http://www.caravelleglobal.com/news-detail.html?newId=1783843089586188289">memorandum of understanding</a> with the government of Gabon to provide dried timber. If it can expand the business model to other governments, Caravelle may have a groundbreaking business on its hands.



CACO stock is up 63% this year, but is still priced at less than $1 per share. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Eco Wave Power (WAVE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1932365063-300x169.png" alt="Environmental protection, renewable, sustainable energy sources. Plant growing in the bulb concept. renewable energy stocks to buy"><div>Source: Proxima Studio / Shutterstock.com</div></div>Eco Wave Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/wave-stock-quote/">WAVE</a>) is a clean energy company that develops electricity from the power of ocean waves. 



If you&rsquo;ve ever been caught in a rough surf you know that even those waves can pack a punch, so imagine the power that an ocean wave can provide should we be able to harness that power and turn it into a clean source of electricity.



The company&rsquo;s floaters can be attached to human-made structures to simplify installation and maintenance. The floaters draw energy from incoming waves by converting the rising and falling motion into a clean energy generation process.



The company currently works with customers in Israel, Portugal, Los Angeles and Gibraltar, a British territory. 



While there was no revenue in the first quarter and the company sustained an operating loss of $659,000, management has high hopes that the company&rsquo;s clean energy solution will be a powerful argument for coastal cities.



WAVE stock is up 79% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-a-rated-penny-stocks-to-beat-june-gloom/">7 A-Rated Penny Stocks to Beat June Gloom</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Penny Stocks to Beat June Gloom

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has shown a robust financial performance in their late...

Jin Medical's Asset Growth Amidst Revenue Dip

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd., a leader in Assistive Technologies manufacturing, has...

JinMed Expands with New High-Tech Facility

ABVC

ALLR

ANTE

APYX

ARGX

BPTH

BROG

CACO

CRDL

CZOO

DERM

DNUT

FLGC

HUBC

HUSA

INCR

INDO

KUKE

LEXX

LGVN

LOBO

LUXH

LXRX

MGRM

NKGN

NSYS

NUVB

OCGN

PHIO

PRAX

PROK

PRZO

PYXS

RENT

RVPH

STRO

TARA

TRML

WAVE

WINT

XFOR

ZJYL

Press Releases

JIN MEDICAL INTERNATIONAL LTD. Secures RMB66 Million in Orders for Innovative Micro-Hyperbaric Oxygen Chamber Equipment

JIN MEDICAL INTERNATIONAL LTD. Empowers "Lao Le Hui" Assisted Bathing Project with Portable Nano-thermal Therapy Bath

JIN MEDICAL INTERNATIONAL LTD. Enters into Memorandum of Understanding to Acquire Medical Equipment Sharing Platform

Opinion

Thinking about buying stock in Applied UV, Alphabet Inc, Alcoa, British American Tobacco, or Jin Medical International?

Comments

Jin Medical International

Jin Medical International (ZJYL) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL